When was Jenthera Therapeutics founded?

Jenthera Therapeutics was founded in 2019.

Where is Jenthera Therapeutics located?

Jenthera Therapeutics is headquartered in Montreal, Canada.

How many employees does Jenthera Therapeutics have?

As of Aug 31, 2026, the latest employee count at Jenthera Therapeutics is 2.

Where does Jenthera Therapeutics rank among its competitors?

Jenthera Therapeutics ranks 419th amongst 548 active competitors, of which 200 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of Jenthera Therapeutics?

Jenthera Therapeutics' top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

Jenthera Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Jenthera is a developer of CRISPR based therapeutics. The company has developed CRISPR based therapeutics offers features such as homology-directed repair, immunogenicity, RNP delivery, CRISPR nuclease.

Key Metrics

Founded Year

2019

Location

Montreal, Canada

Stage

Funding Raised

Investors

adMare BioInnovations & 1 more

Ranked

419^th among 548 active competitors

Employee Count

2 as on Aug 31, 2026

Similar Companies

Alnylam & 683 more

View Jenthera Therapeutics' full profile

Jenthera Therapeutics is a funded company. Jenthera Therapeutics has 2 institutional investors.

View details of Jenthera Therapeutics's funding rounds and investors

The founders of Jenthera Therapeutics is Laurent Ziri.

Here are the details of Jenthera Therapeutics' key team members:

Laurent Ziri: Co-Founder of Jenthera Therapeutics.

View details of Jenthera Therapeutics's Founder profiles and Board Members

Jenthera Therapeutics' employee count trend

Jenthera Therapeutics has 2 employees as of Aug 26. Here is Jenthera Therapeutics's employee count trend over the years:

Employee count trend for Jenthera Therapeutics

Uncover Jenthera Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Jenthera Therapeutics include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Jenthera Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
9th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
419th	Jenthera Therapeutics 2019, Montreal (Canada), Funding Raised	Developer of CRISPR based therapeutics	-	adMare BioInnovations, Beresford Ventures	26/100